Prestige Consumer Healthcare Inc. (PBH) is a leading provider of over-the-counter (OTC) healthcare products. Founded in 1996 and headquartered in Tarrytown, New York, Prestige has established its name in the OTC market by acquiring and investing in well-known brands, while maintaining a customer-centric approach.
In its extensive consumer product portfolio, Prestige Consumer Healthcare offers several leading brands such as Clear Eyes, Compound W, Dramamine, Efferdent, BC Powder and more, that are distributed in multiple channels including mass merchandisers, drug stores, supermarkets, and convenience stores, etc. This wide distribution helps the company to serve a diverse consumer base.
Over the years, Prestige Consumer Healthcare has strived to balance organic growth while undertaking strategic acquisitions that have helped solidify its position in the industry. It acquired DenTek Oral Care Inc., a leader in OTC dental products, in 2016, significantly increasing its portfolio. This followed their previous acquisition of Insight Pharmaceuticals Corporation, a significant player in the women’s health sector, including brands such as Monistat and Summer’s Eve.
The company is committed to delivering products that are trusted by consumers and healthcare professionals. It accomplishes this through rigorous quality testing, ensuring that its products meet the highest standards. The research and development team focuses on innovation, working to create new products and improve existing ones.
Prestige Consume Healthcare Inc. operates under a strategic and disciplined financial model. In 2021 the company reported a top-line annual sales of $938.62 million and a net income of $121.79 million.
Prestige's continued success is a result of its key business strategies including: a focus on core brands, strategic acquisitions, innovations, and a robust supply chain. To further enhance their market stand, they concentrate on investing in high-impact consumer and healthcare professional marketing.
Efforts towards environmental sustainability are also part of Prestige Consumer Healthcare Inc.'s mission. The company aims to reduce its environmental footprint by focusing on energy efficiency, and reducing waste production.
In its over two-decade-long journey, Prestige Consumer Healthcare Inc has cemented its place in the OTC healthcare industry. It continues to prioritize the health and well-being of its consumers providing high-quality, reliable healthcare products all while maintaining strong financial performance.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Argus has raised its target price for Prestige Consumer Healthcare (PBH) to $46.00, identifying it as a leading pure-play over-the-counter healthcare provider. The company boasts a diverse portfolio of strong brands within niche consumer health categories. The current price of PBH stock is $49.46.
This article analyzes Prestige Consumer Healthcare Inc. (NYSE: PBH) using AI models to provide trading strategies and risk allocation insights. It identifies a near-term positive sentiment with a potential shift, a 44.3:1 risk-reward setup targeting a 13.2% gain, and divergent sentiment across different time horizons. The report details specific position, momentum breakout, and risk hedging strategies for traders.
Prestige Consumer Healthcare Inc. (NYSE: PBH) reported a 6.5% sales increase to $266 million in Q1 2027, driven by strong performance in GI and skincare. The company completed strategic acquisitions of Breathe Right and Locorium Health, which are expected to significantly contribute to revenue and diversify its portfolio. Prestige raised its full-year revenue guidance to $1.29-$1.315 billion, anticipating over 20% growth from acquisitions while maintaining 1-3% organic growth.
This article analyzes Prestige Consumer Healthcare Inc. (NYSE: PBH), highlighting weak sentiment across all time horizons and an exceptional 45.8:1 risk-reward short setup. It details institutional trading strategies, including long, breakout, and risk-hedging options, along with multi-timeframe signal analysis. The report suggests a short bias with significant downside potential against minimal risk.
Prestige Consumer Healthcare Inc. announced that its Chairman, President, & CEO Ron Lombardi and CFO and COO Christine Sacco will participate in a fireside chat at the Barclays Global Consumer Conference on September 10, 2026, at 12:45 p.m. ET. A live webcast and replay of the event will be available on the company's investor relations website. Prestige Consumer Healthcare is a leading consumer healthcare company with a diverse portfolio of trusted brands across multiple markets.